FDA As Drug Developer: Voucher For AstraZeneca, Orphan Indication For Wellstat
Hoping to head off shortage of another product, FDA’s intervention gives both Wellstat and AstraZeneca quicker paths to market for their drugs in what could almost be a regulatory fairytale.
You may also be interested in...
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.